Cyclacel Pharmaceuticals Inc

NASDAQ:CYCCUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Yesterday

Show headlines and story abstract

• -- Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000, from 16 hours ago by MT Newswires

  16 hours ago by MT Newswires
  Companies Mentioned: CYCC
  04:06 PM EDT, 05/14/2024 (MT Newswires) -- ...

• Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update, from 16 hours ago by GlobeNewswire

  16 hours ago by GlobeNewswire
  Companies Mentioned: CYCC

• Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update, from 16 hours ago by Dow Jones

  16 hours ago by Dow Jones
  Companies Mentioned: CYCC
  Loss before taxes (4,300) (7,124) Income tax benefit 1,354 1,320 Net loss (2,946) (5,804) Dividend on convertible exchangeable preferred shares - (50) Net loss applicable to common shareholders $ (2,946) $ (5,854) ========= ======= Basic and diluted earnings per common share: Net loss per share -- basic and diluted (common shareholders) $ (2.27) $ (7.00) Net loss per share -- basic and diluted (redeemable common shareholders) $ - $ (7.00) Weighted average common shares outstanding 1,296,547 835,946 ========= ======= CYCLACEL PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEET (In $000s, except share, per share, and liquidation preference amounts) March 31, December 31, 2024 2023 ----------- ---------------- ASSETS Current assets: Cash and cash equivalents $ 2,798 $ 3,378 Prepaid expenses and other current assets 2,037 4,066 ------ ---------- Total current assets 4,835 7,444 Property and equipment, net 7 9 Right-of-use lease asset 79 93 Non-current deposits 1,244 1,259 Total assets $ 6,165 $ 8,805 ====== ========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,200 $ 3,543 Accrued and other current liabilities 3,150 4,618 Total current liabilities 8,350 8,161 Lease liability 21 37 ------ ---------- Total liabilities 8,371 8,198 Stockholders' equity (2,206) 607 ------ ---------- Total liabilities and stockholders' equity $ 6,165 $ 8,805 ====== ==========
  

• Press Release: Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update, from 16 hours ago by Dow Jones

  16 hours ago by Dow Jones
  Companies Mentioned: CYCC
  Loss before taxes (4,300) (7,124) Income tax benefit 1,354 1,320 Net loss (2,946) (5,804) Dividend on convertible exchangeable preferred shares - (50) Net loss applicable to common shareholders $ (2,946) $ (5,854) ========= ======= Basic and diluted earnings per common share: Net loss per share -- basic and diluted (common shareholders) $ (2.27) $ (7.00) Net loss per share -- basic and diluted (redeemable common shareholders) $ - $ (7.00) Weighted average common shares outstanding 1,296,547 835,946 ========= ======= CYCLACEL PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEET (In $000s, except share, per share, and liquidation preference amounts) March 31, December 31, 2024 2023 ----------- ---------------- ASSETS Current assets: Cash and cash equivalents $ 2,798 $ 3,378 Prepaid expenses and other current assets 2,037 4,066 ------ ---------- Total current assets 4,835 7,444 Property and equipment, net 7 9 Right-of-use lease asset 79 93 Non-current deposits 1,244 1,259 Total assets $ 6,165 $ 8,805 ====== ========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,200 $ 3,543 Accrued and other current liabilities 3,150 4,618 Total current liabilities 8,350 8,161 Lease liability 21 37 ------ ---------- Total liabilities 8,371 8,198 Stockholders' equity (2,206) 607 ------ ---------- Total liabilities and stockholders' equity $ 6,165 $ 8,805 ====== ==========